Development of an antibody therapy for the treatment of pneumonia

Jenny Herbert (London, United Kingdom), Jenny Herbert, Timothy Mitchell

Source: International Congress 2016 – Microbiological issues and translational research in respiratory infections
Session: Microbiological issues and translational research in respiratory infections
Session type: Thematic Poster
Number: 2623
Disease area: Respiratory infections

Congress or journal article abstractE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
Jenny Herbert (London, United Kingdom), Jenny Herbert, Timothy Mitchell. Development of an antibody therapy for the treatment of pneumonia. Eur Respir J 2016; 48: Suppl. 60, 2623

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Surfactant-enforced treatment of pseudomonas-induced pneumonia
Source: Annual Congress 2013 –Novel drugs and biomarkers in respiratory medicine
Year: 2013


Modification of empirical antibiotic therapy in community acquired pneumonia
Source: International Congress 2014 – Different interesting issues in respiratory infections: 2
Year: 2014


Dynamic of adherence to guidelines for antibiotic therapy of community-aquired pneumonia (CAP)
Source: Annual Congress 2013 –Antibiotics, resistance and vaccines
Year: 2013


Factors affecting treatment success in community acquired pneumonia (CAP)
Source: Annual Congress 2013 –Pneumonia and sepsis
Year: 2013


Empirical treatment of community-acquired pneumonia after outpatient beta-lactam therapy
Source: International Congress 2016 – Community-acquired pneumonia: from prevention to treatment
Year: 2016


Benefits of co-administration of macrolides and glucocorticosteroids in the treatment of severe community acquired pneumonia
Source: International Congress 2016 – Community-acquired pneumonia: update on prognostic factors and therapeutic strategies
Year: 2016


Predictors of treatment failure in patients with bacteremic pneumococcal community-acquired pneumonia
Source: Annual Congress 2013 –Pneumonia and sepsis
Year: 2013


Colistin therapy for nosocomial pneumonia and nephrotoxicity
Source: Annual Congress 2013 –Antibiotics, resistance and vaccines
Year: 2013

The impact of mixed etiology in community acquired pneumonia (CAP)
Source: International Congress 2014 – Respiratory infections: inflammation and treatment
Year: 2014



Impact of bacterial coinfection on clinical outcomes in pneumococcal pneumonia
Source: International Congress 2015 – Pneumonia: determinants of clinical outcomes and potential strategies to improve its management
Year: 2015


Drug-resistant pathogens prediction scores in CAP, HCAP and immunocompromised
Source: International Congress 2014 – Antibiotics, antifungals and other therapeutic options
Year: 2014


Shortening duration of antibiotic therapy according to clinical stability in patients with community-acquired pneumonia (CAP)
Source: International Congress 2014 – Respiratory infections: inflammation and treatment
Year: 2014


Breakthrough invasive pulmonary aspergillosis (IPA) in patients receiving posaconazole prophylaxis (PPxis)
Source: International Congress 2014 – Antibiotics, antifungals and other therapeutic options
Year: 2014


Immunoglobulin levels and severity of community-acquired pneumonia (CAP)
Source: International Congress 2014 – Pathogenesis and mechanisms of respiratory infections
Year: 2014


Bacteremia in non-HIV community acquired pneumonia
Source: Annual Congress 2013 –Pneumonia and sepsis
Year: 2013


Community adquired legionella pneumophila pneumonia in elderly patients
Source: International Congress 2014 – Epidemiology, scores and outcomes of respiratory infections
Year: 2014

Can the broad-spectrum antibiotics improve the prognoses of high-risk nursing- and healthcare-associated pneumonia?
Source: International Congress 2014 – Epidemiology, scores and outcomes of respiratory infections
Year: 2014


Modern etiology of severe community-acquired pneumonia
Source: International Congress 2016 – Community-acquired pneumonia: risk classes and management issues
Year: 2016


Common organisms causing community acquired pneumonia
Source: Annual Congress 2013 –Bacterial, fungal and mycobacterial infections
Year: 2013


Comparative evaluation of timing of antibiotic intravenous-to-oral switch in pneumonia
Source: International Congress 2014 – Antibiotics, antifungals and other therapeutic options
Year: 2014